Patents by Inventor Uyen Truong Phan

Uyen Truong Phan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer
    Patent number: 11918648
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 5, 2024
    Assignees: MERCK SHARP & DOHME LLC, TRISALUS LIFE SCIENCES, INC.
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20210196819
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: August 21, 2020
    Publication date: July 1, 2021
    Inventors: Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
    Patent number: 10751412
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 25, 2020
    Assignees: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20180169229
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 21, 2018
    Applicants: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying YU, Andrew Evan DENKER, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, David Ross KAUFMAN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • COMBINATION OF AN ANTI-IL-10 ANTIBODY AND A CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20180161427
    Abstract: The present disclosure describes combination therapies comprising an anti-IL-10 antibody or antigen-binding fragment thereof and a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 14, 2018
    Applicants: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying YU, Elliot Keith CHARTASH, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof
    Patent number: 9000128
    Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: April 7, 2015
    Assignee: Bionovion Holding B.V.
    Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
  • Antibodies against a proliferating inducing ligand (APRIL) and methods of use thereof
    Patent number: 8895705
    Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: November 25, 2014
    Assignee: Bionovion Holding B.V.
    Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
  • ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL)
    Publication number: 20130302353
    Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
    Type: Application
    Filed: March 11, 2013
    Publication date: November 14, 2013
    Applicant: BIONOVION HOLDING B.V.
    Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
  • ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL)
    Publication number: 20130295103
    Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
    Type: Application
    Filed: March 11, 2013
    Publication date: November 7, 2013
    Applicant: BIONOVION HOLDING B.V.
    Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
  • ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL)
    Publication number: 20130273064
    Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 17, 2013
    Applicant: BIONOVION HOLDING B.V.
    Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
  • ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL)
    Publication number: 20120195909
    Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
    Type: Application
    Filed: August 24, 2011
    Publication date: August 2, 2012
    Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan